ISRG Stock Recent News
ISRG LATEST HEADLINES
Many products sold by companies aren't must-have items. However, healthcare is a necessity.
Acquisition of distributor business expands Intuitive's investment and footprint in Europe Acquisition of distributor business expands Intuitive's investment and footprint in Europe
Growth stocks tend to beat the market in the long run.
Leading robotic surgery systems developer Intuitive Surgical Inc. NASDAQ: ISRG kicked off the new year by issuing upside guidance for its fourth quarter of 2024. Its da Vinci Surgical System has had a first-mover advantage ever since it launched in 2000, becoming the first commercial robotic surgical platform approved by the FDA.
Intuitive Surgical's share price surged after the company reported 25% YoY revenue growth in the fourth quarter. Despite macro headwinds, robust procedure volumes, international expansion and new product rollouts continue to support growth. While investors probably should look through the current growth surge, particularly given Intuitive's extreme valuation, near term earnings beats could continue to drive the stock higher.
You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.
Evaluate the expected performance of Intuitive Surgical (ISRG) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Intuitive Surgical (ISRG) shares hit another record high Thursday, one day after the medical technology company issued preliminary fourth-quarter and full-year revenue above expectations amid growing demand for its surgical robotics equipment.
Intuitive Surgical (ISRG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.